

1 We claim:

2

3 1. A fluid-imbibing device for delivering an active agent to a fluid  
4 environment of use, said device comprising a water-swellaable semipermeable  
5 material that is received in sealing relationship with the interior surface of one  
6 end of an impermeable reservoir and an active agent to be displaced from the  
7 device when the water-swellaable material swells.

8

9 2. The device of claim 1 wherein the semipermeable material is  
10 selected from the group consisting of plasticized cellulosic materials,  
11 polyurethanes and polyamides.

12

13 3. The device of claim 1 wherein the aspect ratio of the plug is  
14 1:10 to 10:1 length to diameter.

15

16 4. The device of claim 1 wherein the semipermeable material is  
17 assembled into an open end of the reservoir.

18

19 5. The device of claim 1 wherein the semipermeable material is  
20 assembled into a cavity in said reservoir.

21

22 6. The device of claim 5 wherein the cavity is of a shape selected  
23 from the group consisting of a cylindrical, stepped, helical threaded and  
24 spaced configuration.

25

26 7. The device of claim 1 wherein the active agent is selected from  
27 the group consisting of a protein, a peptide or a gene therapy agent.

28

29 8. The device of claim 7 wherein the active agent is an LHRH  
30 agonist or antagonist.

31

1           9.     The device of claim 7 wherein the active agent is leuprolide.

2

3           10.    The device of claim 7 wherein the active agent is selected from  
4 the group consisting of Factor VIII and Factor IX.

5

6           11.    The device of claim 1 wherein the active agent is delivered to a  
7 site remote from the device.

8

9           12.    An implantable device for delivering an active agent to a fluid  
10 environment of use, said device comprising a reservoir and a back-diffusion  
11 regulating outlet in mating relationship, wherein a flow path for the active  
12 agent comprises a pathway formed between the mating surfaces of the  
13 reservoir and the back-diffusion regulating outlet.

14

15           13.    The device of claim 12 where the active agent is delivered at a  
16 rate of 0.02 to 50  $\mu$ l/day.

17

18           14.    The device of claim 12 wherein the active agent is selected from  
19 the group consisting of a protein, a peptide or a gene therapy agent.

20

21           15.    The device of claim 14 wherein the active agent is leuprolide.

22

23           16.    The device of claim 12 wherein the active agent is delivered to a  
24 site remote from the device.

25

26           17.    A device for storing an active agent in a fluid environment of use  
27 during a predetermined administration period, the device comprising a  
28 reservoir containing an active agent, said reservoir being formed at least in  
29 part from a metallic material, the portion of said reservoir contacting said  
30 active agent being non-reactive with the active agent, said metallic material in

1 contact with active agent being formed of a material selected from the group  
2 consisting of titanium and its alloys.

3

4 18. The device of claim 17 wherein the titanium alloy is at least 60%  
5 titanium.

6

7 19. The device of claim 17 wherein the active agent is selected from  
8 the group consisting of a protein, a peptide or a gene therapy agent.

9

10 20. The device of claim 19 wherein the active agent is delivered to a  
11 site remote from the device.

12

13 21. An implantable fluid-imbibing active agent delivery system  
14 comprising an impermeable reservoir and containing a piston that divides the  
15 reservoir into an active agent containing chamber and a water-swella-  
16 ble agent containing chamber, wherein the active agent containing chamber is  
17 provided with a back-diffusion regulating outlet and the water-swella-  
18 ble agent containing chamber is provided with a semipermeable plug; wherein the plug  
19 is releasable from the reservoir at an internal pressure that is lower than the  
20 maximum osmotic pressure generated by the water-swella-  
21 ble agent.

21

22 22. An implantable fluid-imbibing active agent delivery system  
23 comprising an impermeable reservoir and containing a piston that divides the  
24 reservoir into an active agent containing chamber and a water-swella-  
25 ble agent containing chamber, wherein the active agent containing chamber is  
26 provided with a back-diffusion regulating outlet and the water-swella-  
27 ble agent containing chamber is provided with a semipermeable plug; wherein the outlet  
28 is releasable from the reservoir at an internal pressure that is lower than the  
29 maximum osmotic pressure generated by the water-swella-  
30 ble agent.

30

1           23.    A fluid-imbibing implantable active agent delivery system for  
2 delivering an active agent to a fluid environment of use for a predetermined  
3 administration period, wherein the time to start-up is less than 10% of the  
4 predetermined administration period.

5  
6           24.    A method for preparing a fluid-imbibing implantable active agent  
7 delivery system for delivering an active agent to a fluid environment of use for  
8 a predetermined administration period said method comprising injection  
9 molding a semipermeable plug into the end of an impermeable reservoir such  
10 that the semipermeable plug is protected by the reservoir.

11  
12           25.    The method of claim 24 wherein the semipermeable plug  
13 material is a polyurethane based material.

14  
15           26.    The method of claim 24 wherein the semipermeable plug  
16 material is a polyamide based material.

17  
18           27.    The method of claim 24 wherein the semipermeable plug  
19 material is a cellulosic based material.

20  
21           28.    An implantable active agent delivery system for delivering an  
22 active agent to a fluid environment of use, said agent being susceptible to  
23 degradation if exposed to the fluid environment of use prior to delivery, said  
24 system comprising:

25           (a)    a piston that divides the system into a first and second chamber,  
26 the first and second chambers each having an open end;

27           (b)    a water-swellaable agent formulation in the first chamber;

28           (c)    an active agent formulation in the second chamber;

29           (d)    a semipermeable plug in the open end of the first chamber; and

30           (e)    a back-diffusion regulating outlet in the open end of the second  
31 chamber;

1            wherein said system effectively seals the active agent chamber and  
2 isolates it from the environment of use.

3  
4            29.    The system of claim 28 wherein the active agent is selected  
5 from the group consisting of a protein, a peptide or a gene therapy agent.

6  
7            30.    The system of claim 28 wherein the active agent is leuprolide.

8  
9            31.    A back-diffusion regulating outlet useful in an active agent  
10 delivery system for delivering active agent to a fluid environment of use, said  
11 outlet defining a flow path wherein the length, interior cross-sectional shape  
12 and area provide for an average linear velocity of the active agent that is  
13 higher than the linear inward flux of the fluid environment of use.

14  
15           32.    The outlet of claim 31 wherein the flow path is helical in shape.

16  
17           33.    A semipermeable plug useful in an active agent delivery system  
18 for delivering an active agent to a fluid environment of use, said plug being  
19 water-swallowable and expanding linearly in said delivery system to commence  
20 pumping of active agent upon insertion of the delivery system in the fluid  
21 environment of use.

22  
23           34.    An implantable leuprolide delivery system comprising:

24           (a)    an impermeable reservoir;

25           (b)    a piston that divides the reservoir into a first and a second  
26 chamber, the first and second chambers each having an open end;

27           (c)    a water-swallowable agent formulation in the first chamber;

28           (d)    a leuprolide formulation in the second chamber;

29           (e)    a semipermeable plug in the open end of the first chamber; and

30           (f)    a back-diffusion regulating outlet in the open end of the second  
31 chamber;

1            wherein the system effectively seals the second chamber and isolates  
2            the leuprolide formulation from the environment of use.

3

4            35.    The system of claim 34 wherein the reservoir is titanium or a  
5            titanium alloy.

6

7            36.    The system of claim 34 wherein the piston is formed of C-Flex<sup>®</sup>  
8            TPE.

9

10           37.    The system of claim 34 wherein the water-swellaable agent  
11           formulation contains at least about 64 mg NaCl.

12

13           38.    The system of claim 34 wherein the water-swellaable agent  
14           formulation contains NaCl, a gelling osmopolymer and granulation and  
15           processing aids.

16

17           39.    The system of claim 34 further comprising an additive in the first  
18           chamber.

19

20           40.    The system of claim 39 wherein the additive is PEG 400.

21

22           41.    The system of claim 34 wherein the leuprolide formulation is  
23           leuprolide acetate dissolved in DMSO at an assayed content of 37%  
24           leuprolide.

25

26           42.    The system of claim 34 which contains 65 mg leuprolide.

27

28           43.    The system of claim 34 wherein the semipermeable plug is  
29           formed of polyurethane material with 20% water uptake.

30

1           44.    The system of claim 34 wherein the back-diffusion regulating  
2 outlet is made of polyethylene and has a flow path helical in shape with a  
3 diameter between 0.003 and 0.020 inches and a length of 2 to 7 cm.

4  
5           45.    The system of claim 34 which delivers about 0.35  $\mu$ L leuprolide  
6 formulation per day.

7  
8           46.    The system of claim 45 which provides continuous delivery of  
9 leuprolide formulation for about one year.

10  
11          47.    The system of claim 34 which reaches at least about 70%  
12 steady-state delivery by day 14.

13  
14          48.    The system of claim 34 which delivers about 150  $\mu$ g leuprolide  
15 per day.

16  
17          49.    A method of treating a subject suffering from prostatic cancer  
18 comprising administering at least one system of claim 34.

19  
20          50.    An implantable leuprolide delivery system comprising:  
21           (a)    a titanium alloy reservoir;  
22           (b)    a C-Flex<sup>®</sup> TPE piston that divides the reservoirs into a first and  
23 a second chamber, the first and second chambers each having an open end;  
24           (c)    a compressed NaCl-based osmotic engine and a PEG additive  
25 in the first chamber;  
26           (d)    65 mg leuprolide as a leuprolide acetate solution in DMSO in  
27 the second chamber;  
28           (e)    a semipermeable polyurethane plug with 20% water uptake in  
29 the open end of the first chamber; and  
30           (f)    a polyethylene back diffusion regulating outlet with a helical flow  
31 path in the open end of the second chamber;

- 1            wherein the system continuously delivers about 150  $\mu\text{g}$  leuprolide per
- 2    day for about one year after subcutaneous implantation.